Merck (MRK) announced that Winrevair or sotatercept is now authorized for use in Canada in combination with standard pulmonary arterial hypertension or PAH therapy, for the treatment of adults with World Health Organization [WHO] Group 1 PAH and Functional Class II or III.
Sotatercept is the first activin signaling inhibitor therapy for PAH in Canada. This represents a new class of therapy that works by improving the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation in PAH patients.
Winrevair is already approved in the Europe and the U.S. for the treatment of adults with pulmonary arterial hypertension or PAH.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.